The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
P53 expression in breast cancer
Abstract
Immunohistochemical evaluation of 200 primary breast cancers with the anti‐p53 mouse monoclonal antibody (MAb) PAb421 showed positivity in nuclei of malignant cells in 31 cases (15.5%). PAb421+ cases were significantly more frequently epidermal growth factor receptor (EGF‐R)‐positive (67.7%; p < 0.001) and estrogen receptor (ER)‐negative (73.3%; p < 0.001); they displayed surface histocompatibility class‐1 (80.6%; p < 0.01) and II (74.2%; p < 0.05) antigens. Low values for progesterone receptor (mean 67.20 ± 25.2 fmol/mg; p < 0.05) and a high number of cells positive for the proliferationassociated antigen Ki‐67 (log mean 6.88 ± 0.33; p < 0.01) were found in PAb421+ tumors as well as a high number of grade‐3 infiltrating duct carcinomas (70%; p = 0.01). Of the 200 cases of mammary carcinoma, 88 were further analyzed using another human specific anti‐p53 MAb PAb1801, and 40 (45.5%) were found positive. This MAb stained all the PAb421+ cases and was significantly associated with negative ER status (39.5%; p < 0.05) and high Ki‐67 scores (log mean 6.93 ± 0.24; p = 0.001). Analysis of PAb1801+/Pab421− cases for HLA antigens, EGF‐R and ER showed a phenotype similar to that of the p53−ve/ER+ carcinomas, except for the high Ki‐67 score. No differences in age of the patient, number of involved nodes, tumor size, ploidy or labelling index scores were evident between p53+ and − carcinomas. We concluded that p53 in mammary carcinomas is associated with ER‐negative, growth factor receptor‐positive, high‐grade tumors, and is a promising new parameter to evaluate the cellular biology and prognosis of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Bloom, H. J. G., & Richardson, W. W. (1957) · British Journal of Cancer · doi:10.1038/bjc.1957.43 · Cited by 2,925
Gerdes, J., Schwab, U., Lemke, H., & Stein, H. (1983) · International Journal of Cancer · doi:10.1002/ijc.2910310104 · Cited by 2,788
T antigen is bound to a host protein in SY40-transformed cells
LANE, D. P., & CRAWFORD, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,394
Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649
A Detergent‐trypsin method for the preparation of nuclei for flow cytometric DNA analysis
Vindeløv, L. L., Christensen, I. J., & Nissen, N. I. (1983) · Cytometry · doi:10.1002/cyto.990030503 · Cited by 1,639
Richard, J., Sainsbury, C., Needham, G., Farndon, J., Malcolm, A., & Harris, A. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90593-9 · Cited by 892
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation
Parada, L. F., Land, H., Weinberg, R. A., Wolf, D., & Rotter, V. (1984) · Nature · doi:10.1038/312649a0 · Cited by 730
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells
Eliyahu, D., Raz, A., Gruss, P., Givol, D., & Oren, M. (1984) · Nature · doi:10.1038/312646a0 · Cited by 717
BANKS, L., MATLASHEWSKI, G., & CRAWFORD, L. (1986) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1986.tb09919.x · Cited by 495
Cited by
Miller, L. D., Smeds, J., George, J., Vega, V. B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., Liu, E. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506230102 · Cited by 1,268
Increased expression of mutant forms of p53 oncogene in primary lung cancer
Iggo, R., Bartek, J., Lane, D., Gatter, K., Harris, A. L., & Bartek, J. (1990) · The Lancet · doi:10.1016/0140-6736(90)90801-b · Cited by 1,031
Prognostic Factors in Breast Cancer: College of American Pathologists Consensus Statement 1999
Fitzgibbons, P. L., Page, D. L., Weaver, D., Thor, A. D., Allred, D. C., Clark, G. M., Ruby, S. G., O'Malley, F., Simpson, J. F., Connolly, J. L., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0966-pfibc · Cited by 1,016
p53 mutations in colorectal cancer.
Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., & Lane, D. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7555 · Cited by 1,003
p53: oncogene or anti-oncogene?
Lane, D. P., & Benchimol, S. (1990) · Genes & Development · doi:10.1101/gad.4.1.1 · Cited by 795
Role of p53 in Cell Death and Human Cancers
Ozaki, T., & Nakagawara, A. (2011) · Cancers · doi:10.3390/cancers3010994 · Cited by 650
Monoclonal antibody Ki‐67: its use in histopathology
BROWN, D. C., & GATTER, K. C. (1990) · Histopathology · doi:10.1111/j.1365-2559.1990.tb00788.x · Cited by 639
An immunochemical analysis of the human nuclear phosphoprotein p53
Vojtěšek, B., Bártek, J., Midgley, C. A., & Lane, D. P. (1992) · Journal of Immunological Methods · doi:10.1016/0022-1759(92)90122-a · Cited by 531
Bergh, J., Norberg, T., Sjögren, S., Lindgren, A., & Holmberg, L. (1995) · Nature Medicine · doi:10.1038/nm1095-1029 · Cited by 460
Sjogren, S., Inganas, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., & Bergh, J. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.3-4.173 · Cited by 381
Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer
Hong, M. K. H., Macintyre, G., Wedge, D. C., Van Loo, P., Patel, K., Lunke, S., Alexandrov, L. B., Sloggett, C., Cmero, M., Marass, F., et al. (2015) · Nature Communications · doi:10.1038/ncomms7605 · Cited by 372
Contribution of p53 to Metastasis
Powell, E., Piwnica-Worms, D., & Piwnica-Worms, H. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0136 · Cited by 355
Multifactorial analysis of p53 alteration in human cancer: A review
Soussi, T., Legros, Y., Lubin, R., Ory, K., & Schlichtholz, B. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570102 · Cited by 353
Metaplastic breast carcinomas are basal‐like tumours
Reis‐Filho, J. S., Milanezi, F., Steele, D., Savage, K., Simpson, P. T., Nesland, J. M., Pereira, E. M., Lakhani, S. R., & Schmitt, F. C. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02467.x · Cited by 341
p53 expression and prognosis in gastric carcinoma
Martin, H. M., Filipe, M. I., Morris, R. W., Lane, D. P., & Silvestre, F. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500604 · Cited by 321
Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines.
Cheng, J., & Haas, M. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.10.5502 · Cited by 316
Genetic basis for p53 overexpression in human breast cancer.
Davidoff, A. M., Humphrey, P. A., Iglehart, J. D., & Marks, J. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.5006 · Cited by 285
Bártek, J., Bártková, J., Vojtěšek, B., Stašková, Z., Rejthar, A., Kovařík, J., & Lane, D. P. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910460515 · Cited by 276
Leong, C.-O., Vidnovic, N., DeYoung, M. P., Sgroi, D., & Ellisen, L. W. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30866 · Cited by 270
p63 and p73 in human cancer: defining the network
DeYoung, M. P., & Ellisen, L. W. (2007) · Oncogene · doi:10.1038/sj.onc.1210337 · Cited by 266
Jaros, E., Perry, R., Adam, L., Kelly, P., Crawford, P., Kalbag, R., Mendelow, A., Sengupta, R., & Pearson, A. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.273 · Cited by 264
Linderholm, B., Grankvist, K., Wilking, N., Johansson, M., Tavelin, B., & Henriksson, R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1423 · Cited by 254
Mutational spectrum of p53 mutations in primary breast and ovarian tumors
Feki, A., & Irminger-Finger, I. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.07.002 · Cited by 139
“Cellular accumulation of p53 protein is associated with a number of other factors such as estrogen receptor negativity [19–27], progesterone negativity [20,24,28], high histological grade [21,24,28] or nuclear grade [19], erbB2 overexpression [21,24], aneuploidy [20], and high proliferative rate [20,24].”
BackgroundCoutant, C., Rouzier, R., Qi, Y., Lehmann-Che, J., Bianchini, G., Iwamoto, T., Hortobagyi, G. N., Symmans, W. F., Uzan, S., Andre, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1045 · Cited by 64
“may lead to partly different transcriptional consequences and may also have different prognostic or predictive values in these 2 different types of breast cancers (1, 2, 11, 12).”
Günther, T., Schneider-Stock, R., Ryš, J., Niezabitowski, A., & Roessner, A. (1997) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01240122 · Cited by 28
“The association between p53 alterations and negative hormone receptor status, although described in numerous studies, could be recognized by us only tentatively (Bosari et al. 1992; Caleffi et al. 1994; Cattoretti et al. 1988; Isola et al. 1992).”
Background
Metadata
- Authors
- Cattoretti, G., Rilke, F., Andreola, S., D'Amato, L., & Delia, D.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1988-02-15
- Volume
- 41
- Issue
- 2
- Pages
- 178-183
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2105298270
- Cited by
- 601
- References
- 44
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.